Givlaari FAQs

Frequently Asked Questions (FAQs)

What is Alnylam Assist®?

Alnylam Assist® is a comprehensive patient support program that offers truly personalized assistance for patients getting started on treatment with Alnylam products. Each patient prescribed an Alnylam therapy is assigned a dedicated Case Manager as a primary point of contact and will also be connected with a Patient Education Liaison (PEL). The program is designed to provide ongoing support throughout treatment that’s easy for patients and their families to access, with the ability to adapt to support needs over time as those needs may change. See how Alnylam Assist® can support you throughout treatment ›

How do I get started in the Alnylam Assist® program?

In order to enroll in the program, you must be prescribed GIVLAARI and fill out the Start Form with your doctor. Once the form is completed and you've signed it, your doctor can submit the form online or print it out and fax it to Alnylam Assist®. Find out more about getting started ›

What services does Alnylam Assist® offer?

Alnylam Assist® focuses on 3 key areas of support and service for patients and their families: insurance benefit verification, financial assistance options, and disease and treatment education. Within each of these key areas are benefits and services to surround patients and their families with ongoing support during treatment. Find out more about the support and services offered ›

Who are Case Managers?

Case Managers are experienced in helping individuals get started on treatment and providing ongoing support. They will tailor their level of contact based on your personal needs. Your Alnylam Case Manager can help you understand your insurance coverage for GIVLAARI and your options for financial support that you may be eligible for as well as provide you with educational resources. Learn how you can work together with your own personal Case Manager ›

Who are Patient Education Liaisons (PELs)?

PELs have backgrounds in nursing or genetic counseling and are experienced in educating individuals and their families about matters related to acute hepatic porphyria (AHP). PELs can help you in a variety of ways, including providing disease and product education, connecting you to additional resources, and answering questions about treatment with GIVLAARI. Learn about the PEL team and how to get connected ›

What additional resources are available?

In addition to all of the personalized services that are part of Alnylam Assist®, there are also educational and support resources for patients and their families. These include downloadable materials about AHP and GIVLAARI treatment, as well as links to advocacy groups that connect patients to the AHP community. Find out what’s available to support you and your family ›

How can I contact Alnylam Assist®?

Your Case Manager from Alnylam Assist® is available from 8am - 6pm ET, Monday - Friday at 1-833-256-2748.

Alnylam Assist® get started icon

See How to Get Started

Once you decide to begin treatment with GIVLAARI, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Shontae

Call Shontae


Monday - Friday, 8am - 6pm ET

Alylam Separator Triangles


Do not use GIVLAARI® (givosiran) if you have ever had a severe allergic reaction to GIVLAARI.

GIVLAARI can cause:

Severe allergic reaction

Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:

Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
  Breathing problems or wheezing
  Feeling dizzy or fainting
  Rash or hives

If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

Liver problems

Your doctor will check your liver function by doing blood tests:

Before you start using GIVLAARI
  Once a month for the first 6 months of treatment
  And when they think it is needed

If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

Kidney problems

Your doctor will check how your kidneys are working while you are using GIVLAARI.

Injection site reactions

GIVLAARI is given as an injection under the skin (called a "subcutaneous injection"). Reactions to this injection may happen during treatment with GIVLAARI.

Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

What are the common side effects of GIVLAARI?

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.


GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.

For additional information about GIVLAARI, please see full Prescribing Information.